Drug Profile
Sargramostim inhalation
Alternative Names: Aerosol sargramostim; GM-CSF inhalation; Granulocyte-macrophage colony-stimulating factor -Aerosol formulation; Sargramostim - aerosol formulationLatest Information Update: 10 Dec 2007
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Class Adjuvants; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 19 Jul 2013 Biomarkers information updated
- 10 Dec 2007 Discontinued - Phase-I for Lung cancer in USA (Inhalation)
- 20 Jul 2006 No development reported - Phase-I for Lung cancer in USA (Inhalation)